[Immunotherapy of metastatic renal cell carcinoma: report of 28 cases].
To determine the efficacy of IL-2, IFN and Furtulon in patients with metastatic renal cell carcinoma. During the induction phase of the treatment of 28 patients, which lasted 3 months, IL-2 and IFN were administered subcutaneously three times a week at doses of 5 - 20 MU/m(2) and 6 - 9 MU/m(2), Furtulon was administered at doses of 800 - 1,200 mg daily by oral during 28 days a month. The response rate was 46.4%, including 4 complete response (CR), 9 presented with partial response (PR). The three-drugs combination described in this study demonstrates activity. Based on the present data, combined biochemotherapy may be a promising new approach to the therapy of the metastatic renal cell carcinoma.